文献速递细胞病理与分子病理神经与头颈病理

AUS/FLUS甲状腺细针穿刺不同形态学限定词与BRAF、RAS、RET/PTC及PAX8/PPARγ基因改变相关

Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
PubMed 文献 · Cancer Cytopathol · 2018-02-22

该研究对162例AUS/FLUS甲状腺细针穿刺标本按细胞异型性限定词(Hürthle细胞改变、结构异型性、细胞学异型性)进行亚分类,并检测BRAF、N-H-KRAS、RET/PTC及PAX8/PPARγ改变。细胞学异型性在突变阳性组更常见(37.84% vs 16.00%,P<.0084),且特异性地与BRAFV600E点突变相关;RAS是最常见突变(70.27%),但分布于各亚类且与特定限定词或恶性结局无显著关联。结论提示分子与形态学混合亚分类可改善AUS/FLUS恶性风险分层。

要点

  • 细胞学异型性限定词与BRAFV600E突变特异相关,在突变阳性AUS/FLUS中占37.84%。
  • RAS突变最常见(70.27%),但分布于各AUS/FLUS亚类,未与特定限定词或恶性结局显著关联。
  • RET/PTC和PAX8/PPARγ重排罕见(分别为1例和3例)。

核心结论

  • BRAF和RAS突变与不同的AUS/FLUS限定词相关,因而具有不同的恶性风险。
  • 分子与形态学混合亚分类系统可能改善AUS/FLUS甲状腺细针穿刺标本的恶性风险分层。

研究设计与样本

  • 对162例AUS/FLUS甲状腺细针穿刺病例按细胞异型性限定词(Hürthle细胞改变、结构异型性、细胞学异型性)进行亚分类。
  • 检测BRAF、N-H-KRAS、RET/PTC和PAX8/PPARγ突变,并分析限定词与分子改变的相关性。

主要发现

  • 细胞学异型性在突变阳性AUS/FLUS中占37.84%(14/37),在突变阴性中占16.00%(20/125),差异P<.0084。
  • 细胞学异型性特异性携带BRAFV600E点突变,且在可获得的随访中确认恶性。
  • RAS是AUS/FLUS细针穿刺标本中最常见的突变,占70.27%(26/37),P<.0001。
  • RAS突变分布于各AUS/FLUS亚类,未与特定限定词或恶性结局显著相关。
  • RET/PTC重排仅1例,PAX8/PPARγ重排仅3例。

关键数值与推荐

  • 细胞学异型性限定词与突变阳性相关:37.84% vs 16.00%,P<.0084。
  • RAS突变频率70.27%(26/37),P<.0001。
  • RET/PTC重排1例,PAX8/PPARγ重排3例。

临床怎么用

  • 对AUS/FLUS甲状腺细针穿刺标本可结合细胞学异型性限定词与分子检测(尤其BRAF和RAS)进行风险分层。
  • 细胞学异型性限定词提示应关注BRAFV600E突变及较高恶性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Bethesda System for Reporting Thyroid Cytopathology category of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) includes fine-needle aspiration (FNA) specimens that cannot straightforwardly be classified as benign or malignant. To determine whether morphological subcategorization based on atypia qualifiers and molecular testing could improve malignancy risk stratification of AUS/FLUS patients, this study assessed the correlation between these qualifiers and the molecular alterations commonly harbored by thyroid neoplasms. METHODS: A total of 162 AUS/FLUS cases were subcategorized by atypia qualifiers (Hürthle cell changes, architectural atypia, and cytologic atypia [CyA]) and were tested for BRAF, N-H-KRAS, RET/PTC, and paired box 8 (PAX8)/peroxisome proliferator activated receptor γ (PPARg) mutations. RESULTS: CyA was observed more frequently in mutation-positive AUS/FLUS (14 of 37 [37.84%]) than mutation-negative AUS/FLUS (20 of 125 [16.00%]; P < .0084), and it specifically harbored the BRAFV600E point mutation. Malignancy was confirmed in the available follow-up. Conversely, although RAS was the most frequent mutation identified in AUS/FLUS FNA specimens (26 of 37 cases [70.27%]; P < .0001), it was distributed across various AUS/FLUS subcategories and was not significantly associated with a specific atypia qualifier or malignant outcome according to the available follow-up. Rearrangements of both RET/PTC (n = 1) and PAX8/PPARg (n = 3) were rarely retrieved in the FNA samples. CONCLUSIONS: BRAF and RAS mutations are associated with different AUS/FLUS qualifiers and hence have different risks of malignancy. Consequently, a hybrid molecular and morphological subcategorization system could improve the malignancy risk stratification of thyroid FNA samples diagnosed as AUS/FLUS. Cancer Cytopathol 2018;126:317-25. © 2018 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Bellevicine C, Sgariglia R, Migliatico I, et al. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Cancer Cytopathol. 2018. PMID: 29469940. doi:10.1002/cncy.21984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。